Corvus Pharmaceuticals CRVS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's EPS (diluted)?
- Corvus Pharmaceuticals (CRVS) reported EPS (diluted) of -$0.15 in Q1 2026.
- How has Corvus Pharmaceuticals's EPS (diluted) changed year-over-year?
- Corvus Pharmaceuticals's EPS (diluted) decreased by 15.4% year-over-year, from -$0.13 to -$0.15.
- What is the long-term trend for Corvus Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's EPS (diluted) has grown at a -17.1% compound annual growth rate (CAGR), from -$1.06 to -$0.50.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.